Abstract 328P
Background
The presence of the immune-related adverse events (irAEs) has been reported as a preferred marker of the efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients. However, there are only a few studies that focused on the relationship between the efficacy of ICIs and the severity or a high-resolution computed tomography (HRCT) scan pattern of drug-induced lung disorder (DILD).
Methods
We conducted a retrospective study of patients with NSCLC who were treated with ICIs between January 2016 and June 2019 in our institution. We especially focused on the patients who developed DILD during ICIs treatment, and analyzed the clinical information and HRCT pattern of DILD to investigate the prognosis of patients who developed DILD. Assessment of treatment response was evaluated using the response evaluation criteria in solid tumors version 1.1. Severity of DILD was classified by grade according to pneumonitis in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Results
Total 182 patients were enrolled, including 20 patients who received chemotherapy with ICIs. Among the 182 patients, 32 patients (17.6 %) developed DILD and CTCAE grade 1/2/3/4/5 were 10/7/9/2/4 patients, respectively. The median progression-free survival was 100 and 93 days, (P = 0.324, Log-rank Test) and overall survival was 415 and 501 days (P = 0.0951, Log-rank Test) in patients with or without DILD, respectively. The median period from the first ICI treatment to onset of DILD was significantly shorter in the Grade 3/4/5 group than Grade 1/2 group; 22 and 72.5 days, respectively (P = 0.029, Mann-Whitney U test). Analyzing HRCT findings according to ATS/ERS/JRS/ALAT GUIDLINE, patients who presented consolidation had better prognosis than those with comprehensive GGO. In 4 patients with Grade 5 pneumonitis developed with comprehensive GGO and the period from onset of DILD to death was extremely short; median 2 days.
Conclusions
Our retrospective study suggested that development of DILD was not preferred in terms of prognosis in NSCLC patients. Physician should be alerted for the patients who developed early-onset, severe DILD with comprehensive GGO during ICI treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hiroyuki Yamaguchi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract